Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed attachment file name title grouped question UIN question first answered answering member label
tabling member	label

Search

759587

registered interest
date	12/09/2017
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Tidal Power: Swansea Bay
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what is their timescale for making a decision on plans for a Swansea tidal lagoon, following publication of the Hendry Review in January.
tabling member printed	Baroness Randerson
uin	HL1557
answer	answer is ministerial correction date of answer 18/09/2017 answer text <p>The Government is considering the findings of the independent Hendry Review before deciding, in light of the relevant factors, its position on the proposed Swansea Bay Tidal Lagoon project.</p> answering member printed Lord Prior of Brampton question first answered 18/09/2017 11:53:08 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

759589

registered interest
date	12/09/2017
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Electric Vehicles
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to improve the capacity of the electricity grid to cope with additional demand resulting from increased numbers of electric cars and buses.
tabling member printed	Baroness Randerson
uin	HL1559
answer	answer is ministerial correction date of answer 26/09/2017 answer text <p>The Government has set out its ambition for almost all cars and vans to be zero emissions by 2050, and that sales of new conventional cars and vans will end by 2040. By setting these long-term goals, the Government can ensure that there is plenty of time to ready the grid for the mass transition towards cleaner, more efficient vehicles.</p><p>We have regular discussions with all the key parties in the electricity systems – including energy suppliers, network operators and National Grid – to ensure that all parties are prepared for electric vehicle take up. The capacity market is our principal tool for ensuring we have sufficient capacity to meet demand. National Grid use the latest trends in supply and demand (including from electric vehicles) when advising on the volume of capacity to secure through these auctions.</p><p>Distribution Network Operators forecast the likely uptake of plug-in electric vehicles, in discussion with Government, in order to shape their investment plans. Government is also taking powers as part of the Automated and Electric Vehicles Bill to require all new chargepoints sold or installed in the UK to be smart enabled. Smart charging can help reduce the impact of electric vehicles on the electricity network by ensuring that they can flex to the grid’s need, avoiding existing peaks in demand.</p> answering member printed Lord Prior of Brampton question first answered 26/09/2017 15:56:10 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

632754

registered interest
date	09/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether NHS England has undertaken procurement exercises in relation to hepatitis C medicines which have enabled those medicines to be obtained at a lower cost than the cost used for the purposes of appraisal by the National Institute for Health and Care Excellence.
tabling member printed	Baroness Randerson
uin	HL3152
answer	answer is ministerial correction date of answer 17/11/2016 answer text <p>The Department’s Commercial Medicines Unit (DHCMU), rather than NHS England, is responsible for medicines procurement in secondary care.</p><p> </p><p>DHCMU manages, on behalf of the National Health Service in secondary care, a tender process which establishes price framework agreements for hepatitis C medicines. This programme commenced in August 2015 and has resulted in ongoing price reductions. The six-monthly rolling regional tender programme undertaken on behalf of NHS trusts in England has continued to exert a downward pressure on the prices paid (costs) for the new oral hepatitis C medicines.</p><p> </p><p>The evaluation of hepatitis C products by the National Institute for Health and Care Excellence (NICE) is completely separate to the DHCMU tender process. In developing its guidance on several hepatitis C drugs, NICE took into account prices that had been agreed by the DHCMU at the time its guidance was being developed, as the companies provided this information as part their evidence submissions to NICE.</p><p> </p><p>In common with other medicines, where new competing products become available, procurements managed by the DHCMU may secure reduced prices in the years following NICE’s decisions. As with other medicines, NHS England has taken account of the prices DHCMU procurements achieve for hepatitis C medicines to inform the additional investment required in meeting its commitments to roll out the new treatments.</p> answering member printed Lord Prior of Brampton question first answered 17/11/2016 12:55:40 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

632755

registered interest
date	09/11/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, in the light of the UK's commitment to the elimination of viral hepatitis C by 2030 made at the World Health Organisation in May, what measures they are putting in place to achieve this aim in England, and whether they will reconsider the case for a national improvement framework for hepatitis C.
tabling member printed	Baroness Randerson
uin	HL3153
answer	answer is ministerial correction date of answer 21/11/2016 answer text <p>Several key measures contribute to the United Kingdom’s efforts to achieve the aims of the global strategy, including the national programme of screening of blood donors and blood transfusions for blood-borne viruses to ensure safe supplies. 100% of blood donors are screened with quality assured methods, and national guidance and legislation around infection control in healthcare settings includes a policy for healthcare workers to prevent nosocomial transmission of blood-borne viruses. Prevention efforts focus on minimising harm in people who inject drugs through access to opiate substitution therapies and needle syringe exchange programmes, with National Institute for Health and Care Excellence (NICE) guidance <em>Needle and syringe programmes, 2014</em> to support these interventions. NICE guidance <em>Hepatitis B and C testing: people at risk of infection, 2012</em> has also been published to improve uptake of testing for hepatitis C in various settings. Copies of both publications are attached.</p><p> </p><p>While treatment coverage has been historically low, in 2015, approximately 8000 people infected with hepatitis C were estimated to be treated, an increase of around 40% on the previous year which may reflect improved access to and acceptability of treatments, including the new Direct Acting Antivirals.</p><p> </p><p>Public Health England has published hepatitis C metrics for the report <em>Hepatitis C in the UK 2016 report - Working towards its elimination as a major public health threat</em>. A copy of this report is attached.</p> answering member printed Lord Prior of Brampton attachment 1 file name Hepatitis_C_in_the_UK_2016_report.pdf title Hepatitis C in the UK report 2 file name hepatitis-b-and-c-testing-people-at-risk-of-infection.pdf title Testing people at risk of infection 2012 3 file name needle-and-syringe-programmes.pdf title Needle and syringe programmes 2014 question first answered 21/11/2016 15:34:29 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

541747

registered interest
date	21/07/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Blood: Contamination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether they provide a lower level of support for the surviving partners of those infected by hepatitis C through contaminated blood, compared to the surviving partners of those infected by HIV or co-infected, and if so, why.
tabling member printed	Baroness Randerson
uin	HL1424
answer	answer is ministerial correction date of answer 26/07/2016 answer text <p>Under the reformed ex-gratia payment scheme for infected blood announced on 13 July 2016, the partner/spouse at the time of death of a primary beneficiary will be entitled to a £10,000 one-off lump sum where HIV or hepatitis C infection contributed to the death of their partner/spouse. This will apply to those already bereaved, provided they register before the end of this financial year. Anyone newly bereaved from this year will automatically receive the lump sum. Discretionary support, in an enhanced form from financial year 2018/19, will continue to be available to all bereaved partners/spouses.</p> answering member printed Lord Prior of Brampton question first answered 26/07/2016 13:22:10 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

529955

registered interest
date	29/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Shipping: Inspections
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what guidance they have issued to ensure that HIV clinics also test patients annually for hepatitis C.
tabling member printed	Baroness Randerson
uin	HL882
answer	answer is ministerial correction date of answer 12/07/2016 answer text <p>In February 2014 the British Association for Sexual Health and HIV (BASSH) convened an expert working group, including representation from Public Health England, to formally review evidence and produce <em>Recommendations for testing for sexually transmitted infections (STIs) men who have sex with men (MSM). </em>The recommendations are attached.</p><p> </p><p>The National Institute for Health and Care Excellence has also published <em>Hepatitis B and C testing - people at risk of infection</em>, recommending testing to all services users at increased risk of infection. A copy of the guidance is attached.</p> answering member printed Lord Prior of Brampton attachment 1 file name Hepatitis B and C testing - People at risk of infection.pdf title Hepatitis B and C testing - people at risk 2 file name Recommendations for testing for Sexually Transmitted Infections in men who have sex with men.pdf title Recommendations question first answered 12/07/2016 15:22:11 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

529184

registered interest
date	28/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Public Expenditure
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what was NHS England's expenditure in 2015–16 on (1) cancer, (2) HIV, (3) cystic fibrosis, (4) multiple sclerosis, and (5) hepatitis C, and what is the UK planned expenditure in 2016–17 on each.
tabling member printed	Baroness Randerson
uin	HL838
answer	answer is ministerial correction date of answer 07/07/2016 answer text <p>Planned spend figures for specialised commissioning by NHS England at programme of care level are not generally available. However, the hepatitis C budget for 2016/17 has been published and is £191 million.</p><p> </p><p>Actual spend levels by NHS England are analysed to provide a breakdown for the previous year. An exercise to establish these figures is due to begin shortly.</p><p> </p><p>Services for Multiple Sclerosis are commissioned mainly by clinical commissioning groups and spend data is not collected centrally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL839 question first answered 07/07/2016 12:45:32 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

529185

registered interest
date	28/06/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Public Expenditure: South Wales
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what was NHS England's expenditure on all specialised services, disaggregated by different condition areas, in the last financial year, and what is their planned expenditure for the current year.
tabling member printed	Baroness Randerson
uin	HL839
answer	answer is ministerial correction date of answer 07/07/2016 answer text <p>Planned spend figures for specialised commissioning by NHS England at programme of care level are not generally available. However, the hepatitis C budget for 2016/17 has been published and is £191 million.</p><p> </p><p>Actual spend levels by NHS England are analysed to provide a breakdown for the previous year. An exercise to establish these figures is due to begin shortly.</p><p> </p><p>Services for Multiple Sclerosis are commissioned mainly by clinical commissioning groups and spend data is not collected centrally.</p> answering member printed Lord Prior of Brampton grouped question UIN HL838 question first answered 07/07/2016 12:45:32 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

520593

registered interest
date	23/05/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Civil Servants: Pay
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government why NHS England has decided to restrict hepatitis C treatment, with providers subject to a financial penalty if they do not keep within specified numbers, despite those treatments being approved as cost-effective by NICE.
tabling member printed	Baroness Randerson
uin	HL231
answer	answer is ministerial correction date of answer 07/06/2016 answer text <p>The National Institute for Health and Care Excellence (NICE) specifically requires Operational Delivery Networks (ODNs) to prioritise hepatitis C patients on the basis of highest unmet clinical need, as part of a progressive rollout of treatments over the next five years.</p><p> </p><p>NHS England is funding providers to treat patients at the rate outlined in NICE’s guidance, Technology Appraisals 363, 364 and 365, apportioned to local ODNs based on local health needs. Copies of these Technology Appraisals are attached.</p> answering member printed Lord Prior of Brampton attachment 1 file name NICE TA 363.pdf title NICE Technology Appraiasal 363 2 file name NICE TA 364.pdf title NICE Technology Appraisal 364 3 file name NICE TA 365.pdf title NICE Technology Appraisal 365 question first answered 07/06/2016 14:58:53 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson

458653

registered interest
date	08/03/2016
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Hepatitis
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, further to the Written Answer by Lord Prior of Brampton on 11 February (HL5795), when NHS England's plan for future hepatitis C funding will be finalised, how many patients will be able to access hepatitis C treatment via NHS England's plan for future hepatitis C funding, and whether they will place in the Library of the House a copy of NHS England's plan once it is finalised.
tabling member printed	Baroness Randerson
uin	HL6805
answer	answer is ministerial correction date of answer 21/03/2016 answer text <p>Based on the modelling produced by the National Institute for Health and Care Excellence, NHS England has set out the NHS planning assumptions for hepatitis C in March 2016 for the financial year 2016/17. We understand that this has been shared with Members of Parliament and noble Lords, operational delivery networks, pharmaceutical companies and other stakeholders.</p><p>An expected 6,500 patients will have been treated for the 12 months ending March 2016. NHS England and providers are planning for 10,000 patients to be treated in the 12 months from April 2016 to March 2017.</p><p><strong> </strong></p> answering member printed Lord Prior of Brampton question first answered 21/03/2016 12:22:20 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	4230 label Biography information for Baroness Randerson